NEW YORK, NY / ACCESSWIRE / January 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).

"In our view, the strategic sales and marketing partnership with SCIEX is major achievement for PBIO with the potential to be a major catalyst for future sales. During our coverage, PBIO's growth has been restrained by not having enough capital to invest in building a large, skilled sales team with rich industry connections. While not necessarily a panacea for this risk, adding the sales and distribution muscle of a major, worldwide industry partner to PBIO's sales efforts has the potential to be highly impactful. We are hopeful that the SCIEX relationship will result in a material increase in and acceleration of PCT's penetration into the market," stated Ajay Tandon, CEO of SeeThruEquity. "Based on the results over the past year and expectations for the near future, we are maintaining our price target of $1.57 per share."

The report is available here: PBIO January 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on all of these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the update note are as follows:

Strong momentum heading into 2016E with several catalysts

After upbeat presentations by Mr. Schumacher at our November 2015 and January 2016 Microcap Forums in New York and San Francisco, we expect PBIO's momentum to continue into 2016. In 2016E, PBIO is expecting continued top line growth, and the company appears well on its way to this goal having landed a major new strategic partner in SCIEX ? a global life sciences technology leader and a leading company worldwide in the large and growing mass spectrometry industry. With this partnership in hand, we believe PBIO could show rapid and aggressive top line growth in 2016 and beyond. Finally, on the corporate side of the business, the company continues to work towards an up-list of PBIO's shares to a national exchange in early 2016, such as the NASDAQ or NYSE.

New Mass Spectrometry Partner: SCIEX

Given the large size of the biological sample preparation market opportunity relative to the size of PBIO, we were encouraged to hear management announce a new strategic partnership with leading mass spectrometry company SCIEX. SCIEX is a wholly-owned subsidiary of Danaher Corporation (DHR), a $60bn global holding company and impressive partner. In the announcement, SCIEX and PBIO agreed to jointly will promote PBIO's pressure cycling technology (PCT) sample preparation systems, including PCT-HD (PCT High Definition), with SCIEX's SWATH(R) Acquisition based next-generation proteomics, TripleTOF(R) Systems, QTRAP(R) Systems, and Triple Quad Systems. Incorporating PBIO's proprietary PCT technology should enable SCIEX to provide a complete next generation solution for proteomics, increasing the reproducibility and depth of proteomic analysis. The combined solution offers improved sample preparation in research laboratories, enabling scientists to extract more proteins reproducibly from complex sample types, potentially yielding superior biological insights and discoveries from SCIEX's proteomics platform.

Nice momentum in a 2015 filled with significant accomplishments

Led by experienced life sciences CEO Richard T. Schumacher, PBIO completed a watershed year in 2015. The company generated record quarterly sales -- reaching $0.58mn in 3Q15 versus $0.32mn in 3Q14 and guidance of $0.5mn ? while advancing the adoption of its patented and enabling PCT platform throughout the industry with an expanding number of installments and new customers, many of whom are key opinion leaders in the life sciences industry. Assuming the company meets our estimates for 4Q15, we expect it will have grown revenues by approximately 35% in 2015, with guidance for further growth in the year ahead. PBIO has also succeeded in surpassing its goal of raising $5mn in a private placement over the last six months, which has been used to clean up its balance sheet and allow investments in sales, marketing and operations.

PIPE exceeds $5mn goal; announces over-subscription

On January 11, 2016, PBIO announced that it had raised an additional $250,000 in new capital in the fifth closing of a financing it started in July 2015 ? exceeding management's goal of raising $5mn through its Private Placement (PIPE) over the last six months. PBIO announced it is opening a $1.25mn over-subscription for the offering, raising cumulative potential proceeds to $6.25mn. PBIO's balance sheet has been a key item to watch in our coverage of the company, as management indicated at the outset of 2015 that it would seek to raise new capital in order to eliminate its variable rate (floorless) convertible notes and fund growth in its sales and marketing team. Management has followed through on this promise, announcing concurrent with a $0.7mn financing in December that it had successfully eliminated the final portion of the remaining variable rate (floorless) convertible notes. Despite PBIO never having allowed the variable rate floorless notes to convert under the terms of the loans, we view the elimination of this risky debt as a significant accomplishment ? as the floorless conversion feature carried a major risk of shareholder dilution. In all, PBIO was able to pay down over $2.7mn in variable rate loans while still exceeding its lofty sales goals in the first three quarters of 2015.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity